Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

被引：4
|
作者：
Rodrigues, M. J. [1 ,2 ]
Albiges-Sauvin, L. [2 ,3 ]
Wassermann, J. [2 ,4 ]
Cottu, P. H. [1 ]
机构：
[1] Inst Curie, Dept Med Oncol, Paris, France
[2] AERIO, Paris, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Hop Rene Huguenin, Inst Curie, Dept Med Oncol, St Cloud, France
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷 / 11期
关键词：
CANCER;
D O I：
10.1093/annonc/mdr308
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2530 / 2530
页数：1
相关论文
共 50 条
  • [31] A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer
    Yap, Kelly Khai Li
    Tripathy, Debu
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (01) : 11 - 15
  • [32] Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis
    Lv, Shuzhen
    Wang, Yunchao
    Sun, Tao
    Wan, Donggui
    Sheng, Lijun
    Li, Wei
    Zhu, Huayun
    Li, Yanping
    Lu, Janice
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (7-8) : 450 - 455
  • [33] BENEFIT OF ADJUVANT TRASTUZUMAB WITH CHEMOTHERAPY (ATWC) IN T1N0 HER2 POSITIVE BREAST CANCER-INTERIM RESULTS
    Kanjanapan, Y.
    Yip, D.
    Dahlstrom, J.
    Craft, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 57 - 57
  • [34] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
    Tomas Baldassarre
    Peter Truesdell
    Andrew W. Craig
    Breast Cancer Research, 19
  • [35] Prognostic value of adjuvant chemotherapy for hormone receptor-negative T1a and T1bN0M0 breast cancer patients
    Liu, Yaxiong
    Li, Honghui
    Li, Jinsong
    Wei, Changlong
    Zeng, Jinsheng
    Tian, Qiuhong
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [36] Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
    Rupert Bartsch
    Catharina De Vries
    Ursula Pluschnig
    Peter Dubsky
    Zsuzsanna Bago-Horvath
    Simon P Gampenrieder
    Margaretha Rudas
    Robert M Mader
    Andrea Rottenfusser
    Christoph Wiltschke
    Michael Gnant
    Christoph C Zielinski
    Guenther G Steger
    BMC Cancer, 9
  • [37] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
    Baldassarre, Tomas
    Truesdell, Peter
    Craig, Andrew W.
    BREAST CANCER RESEARCH, 2017, 19
  • [38] Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
    Bartsch, Rupert
    De Vries, Catharina
    Pluschnig, Ursula
    Dubsky, Peter
    Bago-Horvath, Zsuzsanna
    Gampenrieder, Simon P.
    Rudas, Margaretha
    Mader, Robert M.
    Rottenfusser, Andrea
    Wiltschke, Christoph
    Gnant, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    BMC CANCER, 2009, 9 : 367
  • [39] Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1
    Dogan, Izzet
    Ahmed, Melin Aydan
    Yildiz, Anil
    Vatansever, Sezai
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (03) : 484 - 488
  • [40] Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
    Cao, F.
    Ma, Z.
    Hu, G.
    Zhu, X.
    Li, S.
    Chen, S.
    Chen, B.
    Li, Z.
    Wu, W.
    Ji, X.
    Shu, J.
    Tao, D.
    Hu, X.
    Zheng, M.
    Wang, O.
    Feng, Q.
    Hao, J.
    Li, X.
    BREAST, 2023, 68 : S16 - S16
12345